Background: Crohn's disease and ulcerative colitis are inflammatory bowel diseases (IBDs) with a rapidly growing worldwide incidence. The last decades presented rapid progress in pharmacological treatment leading in many cases to clinical and endoscopic remission, including biological treatment with anti-TNF agents. Aim: The exact timing of introduction, optimization and maintenance of anti-TNF therapy in IBDs is not thoroughly covered in current guidelines. Methods: We used the Delphi panel methodology to gather the IBD experts' views and achieve consensus for clinical recommendations on introducing and maintaining anti-TNF therapy for patients with IBDs. Results: Twelve recommendations achieved a high level of consensus in two assessment rounds by 52 (1st round) and 47 (2nd round) IBD experts. Conclusion: In many clinical situations, the early use of anti-TNF therapy is recommended. Nowadays, the cost-efficacy profile of anti-TNF biosimilars makes them the first-line drug in a substantial proportion of patients, thus providing the opportunity to increase access to biological therapy.
Timing of proper introduction, optimization and maintenance of anti-TNF therapy in IBD: Results from a Delphi consensus / Ardizzone, Sandro; Armuzzi, Alessandro; Caprioli, Flavio; Castiglione, Fabiana; Danese, Silvio; Daperno, Marco; Fantini, Massimo Claudio; Fries, Walter; Principi, Maria Beatrice; Savarino, Edoardo; Gionchetti, Paolo. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1878-3562. - ELETTRONICO. - 56:1(2024), pp. 98-105. [10.1016/j.dld.2023.09.003]
Timing of proper introduction, optimization and maintenance of anti-TNF therapy in IBD: Results from a Delphi consensus
Gionchetti, Paolo
2024
Abstract
Background: Crohn's disease and ulcerative colitis are inflammatory bowel diseases (IBDs) with a rapidly growing worldwide incidence. The last decades presented rapid progress in pharmacological treatment leading in many cases to clinical and endoscopic remission, including biological treatment with anti-TNF agents. Aim: The exact timing of introduction, optimization and maintenance of anti-TNF therapy in IBDs is not thoroughly covered in current guidelines. Methods: We used the Delphi panel methodology to gather the IBD experts' views and achieve consensus for clinical recommendations on introducing and maintaining anti-TNF therapy for patients with IBDs. Results: Twelve recommendations achieved a high level of consensus in two assessment rounds by 52 (1st round) and 47 (2nd round) IBD experts. Conclusion: In many clinical situations, the early use of anti-TNF therapy is recommended. Nowadays, the cost-efficacy profile of anti-TNF biosimilars makes them the first-line drug in a substantial proportion of patients, thus providing the opportunity to increase access to biological therapy.File | Dimensione | Formato | |
---|---|---|---|
Timing of proper introduction and optimization.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione
1.58 MB
Formato
Adobe PDF
|
1.58 MB | Adobe PDF | Visualizza/Apri |
ScienceDirect_files_23Apr2024_08-40-24.551.zip
accesso aperto
Tipo:
File Supplementare
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione
69.52 kB
Formato
Zip File
|
69.52 kB | Zip File | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.